Evidence map›Paper›PMID 38666458›Full record

ArticleCardiovascular research2024

Serine protease inhibitor, SerpinA3n, regulates cardiac remodelling after myocardial infarction.

Qihao Sun, Wei Chen, Rimao Wu, Bo Tao, Ping Wang, Baiming Sun, Juan F Alvarez, Feiyang Ma, David Ceja Galindo, Sean P Maroney and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Drug design, development and therapy · 2026
    Article
  9. Article
  10. Review
  11. Acute kidney injury disrupts cardiac remodeling via SerpinA3N.bioRxiv : the preprint server for biology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Qihao SunDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Wei ChenDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Rimao WuDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Bo TaoDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Ping WangDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Baiming SunDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Juan F AlvarezDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Feiyang MaDivision of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-6260-0787
David Ceja GalindoBiochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Sean P MaroneyBiochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Anthony J SaviolaBiochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Kirk C HansenBiochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Shen LiDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
Arjun DebDivision of Cardiology, Department of Medicine, University of California, 675 Charles E Young Drive South, Los Angeles, California, 90095 CA, USA.
California NanoSystems Institute · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · US

Funding

Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failureR01HL169217 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Arjun Deb · 2023 to 2026
$3.0M
Role of GPNMB in cardiac remodelingR01HL152176 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2021 to 2024
$2.8M
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injuryR01HL149658 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2020 to 2023
$2.2M
Adenine metabolism in cardiac repairR01HL171307 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Arjun Deb · 2024 to 2026
$2.2M
Role of collagen heterogeneity in remodeling of acute and chronic heart scarsR01HL149687 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN, PELLEGRINI, MATTEO · 2020 to 2023
$2.0M
Role of macrophages in regulating cardiac muscle metabolismR01HL176691 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Arjun Deb · 2025 to 2026
$1.5M
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma ElasticumR01AR075867 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2020 to 2023
$1.4M
Department of Defense, USA PR190268National Institutes of Health, USA HL149658NHLBI NIH HHS R01 HL149658NHLBI NIH HHS R01 HL149687NHLBI NIH HHS R01 HL152176NHLBI NIH HHS R01 HL169217NHLBI NIH HHS R01 HL171307NHLBI NIH HHS R01 HL176691NIAMS NIH HHS R01 AR075867NIDDK NIH HHS R01 DK132735
6 · The paper itself

Abstract

aimsFollowing myocardial infarction (MI), the heart repairs itself via a fibrotic repair response. The degree of fibrosis is determined by the balance between deposition of extracellular matrix (ECM) by activated fibroblasts and breakdown of nascent scar tissue by proteases that are secreted predominantly by inflammatory cells. Excessive proteolytic activity and matrix turnover has been observed in human heart failure, and protease inhibitors in the injured heart regulate matrix breakdown. Serine protease inhibitors (Serpins) represent the largest and the most functionally diverse family of evolutionary conserved protease inhibitors, and levels of the specific Serpin, SerpinA3, have been strongly associated with clinical outcomes in human MI as well as non-ischaemic cardiomyopathies. Yet, the role of Serpins in regulating cardiac remodelling is poorly understood. The aim of this study was to understand the role of Serpins in regulating scar formation after MI. METHODS AND

resultsUsing a SerpinA3n conditional knockout mice model, we observed the robust expression of Serpins in the infarcted murine heart and demonstrate that genetic deletion of SerpinA3n (mouse homologue of SerpinA3) leads to increased activity of substrate proteases, poorly compacted matrix, and significantly worse post-infarct cardiac function. Single-cell transcriptomics complemented with histology in SerpinA3n-deficient animals demonstrated increased inflammation, adverse myocyte hypertrophy, and expression of pro-hypertrophic genes. Proteomic analysis of scar tissue demonstrated decreased cross-linking of ECM peptides consistent with increased proteolysis in SerpinA3n-deficient animals.

conclusionOur study demonstrates a hitherto unappreciated causal role of Serpins in regulating matrix function and post-infarct cardiac remodelling.

Indexed as

Disease Models, AnimalFibrosisMice, KnockoutMyocardial InfarctionMyocardiumVentricular RemodelingAcute-Phase ProteinsAnimalsExtracellular MatrixMaleMice, Inbred C57BLMyocytes, CardiacSerpinsVentricular Function, LeftAcute-Phase ProteinsSerpina3n protein, mouseSerpinsCardiac fibrosisExtracellular matrixMyocardial infarctionRemodellingSerine proteasesSerpin

Identifiers

PMID38666458
PMCPMC12098007
OpenAlexW4395677510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.